Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
Novocure (NVCR) will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual SNO Meeting. The presentations include research on newly designed arrays for efficient TTFields delivery in mouse studies, optimal positioning of Head Flexible Electrodes (HFE) for infratentorial brain tumors, and a subgroup analysis of IDH-mutant glioblastoma patients using real-world data from the xCures platform. More than 20 independent studies of TTFields will be presented at the meeting. The company will also host a sponsored symposium on TTFields therapy's impact on patient outcomes.
Novocure (NVCR) presenterà nuovi dati sulla sua terapia con Tumor Treating Fields (TTFields) per il glioblastoma al 29° Meeting Annuale della SNO. Le presentazioni includono ricerche su array progettati recentemente per una consegna efficiente dei TTFields negli studi sui topi, il posizionamento ottimale di elettrodi flessibili per la testa (HFE) per i tumori cerebrali infratentoriali, e un'analisi di sottogruppo di pazienti con glioblastoma mutante IDH utilizzando dati del mondo reale dalla piattaforma xCures. Più di 20 studi indipendenti sui TTFields saranno presentati durante il meeting. L'azienda ospiterà anche un simposio sponsorizzato sull'impatto della terapia TTFields sui risultati per i pazienti.
Novocure (NVCR) presentará nuevos datos sobre su terapia con Tumor Treating Fields (TTFields) para glioblastoma en el 29° Encuentro Anual de la SNO. Las presentaciones incluyen investigaciones sobre nuevas matrices diseñadas para una entrega eficiente de TTFields en estudios con ratones, la posición óptima de Electrodos Flexibles para la Cabeza (HFE) para tumores cerebrales infratentoriales, y un análisis de subgrupo de pacientes con glioblastoma mutante IDH utilizando datos del mundo real de la plataforma xCures. Más de 20 estudios independientes sobre TTFields serán presentados en la reunión. La empresa también organizará un simposio patrocinado sobre el impacto de la terapia TTFields en los resultados de los pacientes.
Novocure (NVCR)는 제29회 연례 SNO 회의에서 교모세포종에 대한 Tumor Treating Fields (TTFields) 요법에 대한 새로운 데이터를 발표할 예정이다. 발표 내용에는 쥐 연구에서 효율적인 TTFields 전달을 위한 새로 설계된 배열, 아래쪽 뇌종양을 위한 헤드 유연 전극 (HFE)의 최적 위치, 그리고 xCures 플랫폼의 실제 데이터를 사용한 IDH-돌연변이 교모세포종 환자에 대한 하위 그룹 분석이 포함된다. TTFields에 대한 20개 이상의 독립 연구가 회의에서 발표될 예정이다. 회사는 또한 환자 결과에 대한 TTFields 요법의 영향을 주제로 한 후원 심포지엄을 개최할 예정이다.
Novocure (NVCR) présentera de nouvelles données sur sa thérapie avec les Tumor Treating Fields (TTFields) pour le glioblastome lors de la 29ème réunion annuelle de la SNO. Les présentations incluent des recherches sur de nouveaux dispositifs conçus pour une livraison efficace des TTFields dans des études sur des souris, le positionnement optimal des Électrodes Flexibles de Tête (HFE) pour les tumeurs cérébrales infratentoriales, et une analyse de sous-groupe de patients atteints de glioblastome mutant IDH utilisant des données du monde réel de la plateforme xCures. Plus de 20 études indépendantes sur les TTFields seront présentées lors de la réunion. L'entreprise organisera également un symposium sponsorisé sur l'impact de la thérapie TTFields sur les résultats des patients.
Novocure (NVCR) wird auf dem 29. Jahresmeeting der SNO neue Daten zu seiner Tumor Treating Fields (TTFields) Therapie für Glioblastom präsentieren. Die Präsentationen umfassen Forschung zu neu gestalteten Arrays für eine effiziente TTFields-Abgabe in Mäuse-Studien, die optimale Positionierung von Flexiblen Kopf-Elektroden (HFE) für infratentoriale Gehirntumoren sowie eine Subgruppenanalyse von IDH-mutierten Glioblastom-Patienten, die reale Daten von der xCures-Plattform nutzen. Mehr als 20 unabhängige Studien zu TTFields werden auf dem Meeting vorgestellt. Das Unternehmen wird auch ein gesponsertes Symposium zur Auswirkung der TTFields-Therapie auf die Patientenergebnisse abhalten.
- Development of new Head Flexible Electrodes (HFE) for improved treatment delivery
- Expansion of research into new applications for TTFields therapy
- Multiple independent studies supporting TTFields technology
- None.
Insights
This conference presentation news is categorized as not impactful for immediate investor consideration. While the data presentations may be scientifically interesting, they represent routine academic and research updates rather than market-moving developments. The presentations focus on preclinical mouse studies, array design optimization and retrospective real-world data analysis - none of which constitute significant catalysts that would materially affect NVCR's near-term business prospects or stock performance.
The conference presentations lack concrete financial implications, new product approvals, or pivotal clinical trial results that would typically move markets. While ongoing research is important for long-term development, these types of regular scientific conference updates are considered normal course of business for biotech companies.
ROOT,
Novocure will present the results of its work to design arrays that will allow efficient and stable delivery of TTFields in mouse studies as well as research identifying the optimal positioning of its newly approved Head Flexible Electrodes (HFE) transducer arrays for infratentorial brain tumors. Novocure will also present a new subgroup analysis of patients from the xCures real-world data platform that assesses the results of treatment with TTFields in people with isocitrate dehydrogenase (IDH)-mutant glioblastoma.
Novocure’s SNO 2024 Data Presentation Details
Oral Presentation (Abstract #TMOD-09): Newly designed Tumor Treating Fields (TTFields) arrays for the mouse head demonstrate efficacy for treatment of glioblastoma
Presenting Author: Moshe Giladi, Novocure Ltd,
Date/Time: Sunday, November 24; 8:30 –10:00 a.m. CST
Poster INNV-14: Outcomes of patients with isocitrate dehydrogenase-mutant WHO Grade 4 astrocytoma treated with Tumor Treating Fields (TTFields) therapy: a real-world analysis
Presenting Author: Jennifer M. Connelly, Department of Neurology, Medical College of
Date/Time: Friday, November 22; 7:30 – 9:30 p.m. CST
Poster INNV-11: Delivery of TTFields to the infratentorial brain using HFE arrays
Presenting Author: Dheeraj Bhavanasi, Novocure
Date/Time: Friday, November 22; 7:30 – 9:30 p.m. CST
In addition, more than 20 independent preclinical, translational, real-world evidence and clinical studies of TTFields will be presented at the 2024 SNO Annual Meeting. Abstracts can be viewed here: https://academic.oup.com/neuro-oncology/issue/26/Supplement_8
Novocure will also host a sponsored symposium, From Evidence to Practice: Impact of TTFields Therapy on Patient Outcomes, which will be held Friday, November 22, 12:45 –1:45 p.m. CST in Meeting Room: 351 (Level 3 at the George R. Brown Convention Center).
About Tumor Treating Fields
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multimechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors.
To learn more about TTFields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.com.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Novocure has several additional ongoing or completed clinical trials exploring the use of Tumor Treating Fields therapy in the treatment of glioblastoma, non-small cell lung cancer and pancreatic cancer.
Novocure’s global headquarters is located in Root Switzerland, with
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “could” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 22, 2024, and subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121815294/en/
Investors:
Ingrid Goldberg
investorinfo@novocure.com
Media:
Catherine Falcetti
media@novocure.com
Source: Novocure
FAQ
What new TTFields therapy data will Novocure (NVCR) present at SNO 2024?
How many independent studies of Novocure's (NVCR) TTFields will be presented at SNO 2024?
When is Novocure's (NVCR) sponsored symposium at SNO 2024?
